SEARCH

SEARCH BY CITATION

References

  • 1
    Maylin S, Martinot M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 8219.
  • 2
    Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51: 11226.
  • 3
    Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Int 2013; 33(Suppl 1): 93104.
  • 4
    Jacobson I, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment-nave patients: results from QUEST-1, a phase III trial. International Liver Congress, Amsterdam, poster 1425, 2013.
  • 5
    Manns M, Marcellin P, Poordad FP, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype -1 infection in treatment-naıve patients: results from QUEST-2, a phase III trial. International Liver Congress, Amsterdam, abstract 1413, 2013.
  • 6
    Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naive patients: efficacy in difficult-to-treat patient sub-populations in the QUEST 1 and 2 phase III trials. AASLD 2013. Abstract 1122.
  • 7
    Lawitz E, Forns X, Zeuzem S, et al. Simeprevir (TMC435) with Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients who Relapsed After Previous Interferon-Based Therapy: Results from PROMISE, a Phase III trial [abstract869b]. Presented at Digestive Disease Week; 18–21 May; 2013.
  • 8
    Forns X, Lawitz E, Zeuzem S, et al. Simeprevir (TMC435) with peg-interferon α-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub-populations in the PROMISE phase III trial. AASLD 2013. Abstract 1092.
  • 9
    Sulkowski MS, Asselah T, Lalezari J, et al. Faldaprevir combined with peginterferon alfa-2a and ribivirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology 2013; 57: 214354.
  • 10
    Sulkowski MS, Bourlière M, Bronowicki JP, et al. Faldaprevir combined with peginterferon alfa-2a and ribivirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 2013; 57: 215563.
  • 11
    Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 6309.
  • 12
    Ferenci P, Asselah T, Foster GR, et al. Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naive patients: final results from STARTVerso1, a randomised double blind placebo-controlled phase III trial. 48th Annual Meeting of the EASL 2013. Abstract 1416.
  • 13
    Jensen D, Asselah T, Dieterich D, et al. A pooled analysis of two randomized, double-blind placebo-controlled Phase III trials (STARTVerso1&2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment- naïve patients with chronic hepatitis C genotype-1 infection. AASLD 2013; Abstract 1088.
  • 14
    Jacobson I, Asselah T, Ferenci P, et al. STARTVerso3: a randomized, double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection. AASLD 2013; Abstract 1100.
  • 15
    Rockstroh JK, Nelson M, Soriano V, et al. STARTVerso 4 phase III trial of faldaprevir plus peg interferon alfa-2a and ribavirin (PR) in patients with HIV and HCV genotype 1 coinfection: end of treatment response. AASLD 2013. Abstract 1099.
  • 16
    Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 187887.
  • 17
    Marcellin P, Cooper C, Balart L, et al. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection. Gastroenterology 2013; 145: 790800.
  • 18
    Pol S, Ghalib RH, Rustgi VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012; 12: 6717.
  • 19
    Bronowicki JP, Pol S, Thuluvath PJ, et al. Randomized study of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antiviral Ther, 2013, in press.
  • 20
    Manns M, Vierling JM, Bacon BR, et al. High sustained viral response of MK-5172 with pegylated interferon alfa-2b and ribavirin in HCV genotype-1 treatment naive non-cirrhotic patient (EASL). J Hepatol, 2013; 58: Abstract 66.
  • 21
    Asselah T, De Muynck S, Broet P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2011; 56: 52732.
  • 22
    Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 2012; 57: 111025.
  • 23
    Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368: 4553.
  • 24
    Kowdley KV, Lawitz E, Poordad F, et al. Safety and efficacy of interferon-free regimens of ABT- 450/R, ABT-267, ABT-333 + /- ribavirin in patients with chronic HCV GT1 infection: results from the Aviator study. J Hepatol 2013; 58(Suppl 1): A3.
  • 25
    Jacobson IM, Ghalib RH, Rodriguez-Torres M, et al. Simeprevir plus sofosbuvir with or without RBV in genotype 1 treatment-naïve and prior null responder patients: COSMOS. Hepatology 2013, AASLD; LB3.